FDA Authorizes Johnson & Johnson Single-Dose COVID Vaccine

FDA grants Emergency Use Authorization for the Johnson & Johnson (Janssen) vaccine — the first single-dose COVID vaccine in the U.S. and the first using a human adenovirus vector. With ~66% efficacy against moderate disease and ~85% against severe disease, J&J becomes critical for hard-to-reach populations who cannot make two appointments.